<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174432</url>
  </required_header>
  <id_info>
    <org_study_id>TR03ext</org_study_id>
    <secondary_id>2013-005628-41</secondary_id>
    <nct_id>NCT02174432</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis</brief_title>
  <official_title>An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER
      tablets during a treatment period of up to 50 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, frequency and nature of Treatment Emergent Adverse Events (TEAEs) during Treatment by achieved dose</measure>
    <time_frame>Week 4, Week 50</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Prurigo Nodularis</condition>
  <condition>Nodularis Prurigo</condition>
  <condition>Prurigo</condition>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER 90mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER 120 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER 180 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER 90 mg BID</intervention_name>
    <description>nalbuphine HCl ER 90 mg BID for up to 50 weeks</description>
    <arm_group_label>nalbuphine HCl ER 90 mg</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER 120 mg BID</intervention_name>
    <description>nalbuphine HCl ER 120 mg BID for up to 50 weeks</description>
    <arm_group_label>nalbuphine HCl ER 120 mg</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER 180 mg BID</intervention_name>
    <description>nalbuphine HCl ER 180 mg BID for up to 50 weeks</description>
    <arm_group_label>nalbuphine HCl ER 180 mg</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed participation in the TR03 study

        Exclusion Criteria:

          -  Medical condition or other factors that in the opinion of the Investigator may
             interfere with the conduct of the study.

          -  Subject is a pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Sciascia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevi Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Itch</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>Nalbupine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

